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Ruthenium complexes offer the potential of reduced toxicity, a novel mechanism of action, non-cross resistance and a
different spectrum of activity compared to platinum containing compounds. Thirteen novel ruthenium(II) organometallic arene
complexes have been evaluated for activity (in vitro and in vivo) in models of human ovarian cancer, and cross-resistance
proﬁles established in cisplatin and multi-drug-resistant variants. A broad range of IC50 values was obtained (0.5 to 4100 mM)
in A2780 parental cells with two compounds (RM175 and HC29) equipotent to carboplatin (6 mM), and the most active
compound (HC11) equipotent to cisplatin (0.6 mM). Stable bi-dentate chelating ligands (ethylenediamine), a more hydrophobic
arene ligand (tetrahydroanthracene) and a single ligand exchange centre (chloride) were associated with increased activity.
None of the six active ruthenium(II) compounds were cross-resistant in the A2780cis cell line, demonstrated to be 10-fold
resistant to cisplatin/carboplatin by a mechanism involving, at least in part, silencing of MLH1 protein expression via
methylation. Varying degrees of cross-resistance were observed in the P-170 glycoprotein overexpressing multi-drug-resistant
cell line 2780
AD that could be reversed by co-treatment with verapamil. In vivo activity was established with RM175 in the
A2780 xenograft together with non-cross-resistance in the A2780cis xenograft and a lack of activity in the 2780
AD xenograft.
High activity coupled to non cross-resistance in cisplatin resistant models merit further development of this novel group of
anticancer compounds.
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Metal complexes remain an important resource for the generation
of chemical diversity in the search for novel therapeutic and diag-
nostic agents, especially in the arena of anticancer drug
development (Guo and Sadler, 1999). Cis-dichlorodiammine plati-
num(II) (cisplatin) represents one of the most active and clinically
useful agents used in the treatment of cancer, achieving cures in
testicular cancer and high response rates in ovarian and small cell
lung cancer (Giaccone, 2000). Evidence from both pre-clinical
studies and clinical investigations has strongly implicated DNA as
the biologic target for cisplatin through the formation of irreversi-
ble adducts via the process of ligand exchange (Jamieson and
Lippard, 1999; Kelland, 2000). However, in common with many
other cytotoxic drugs, cisplatin induces normal tissue toxicity,
particularly to the kidney, and the development of acquired drug
resistance can occur in initially responsive disease types (ovarian
and small cell lung) or be present as intrinsic drug resistance in
less-responsive disease types (non-small cell lung and colon) (Giac-
cone, 2000).
Based predominately on evidence from cell lines, the mechanis-
tic basis for cisplatin resistance appears to be multi-factorial,
involving drug transport defects (both reduced uptake and active
efﬂux), detoxiﬁcation by interaction with cellular nucleophiles,
modulations in DNA repair pathways, and altered cellular signal-
ling responses downstream of DNA damage (Fink et al, 1998;
Johnson et al, 1998; Wang et al, 2000). A variety of approaches
have been adopted to overcome both de novo and acquired cispla-
tin resistance, ranging from broad-based programmes of new
platinum analogue design to speciﬁc attempts to modulate a single
pathway of resistance (Judson and Kelland, 2000; Mimnaugh et al,
2000; Plumb et al, 2000).
The metal ruthenium (Ru) possesses several favourable chemical
properties that indicate it may be a strong candidate to form a
basis for rational anticancer drug design (Clarke et al, 1999; Allar-
dyce and Dyson, 2001). Ru complexes demonstrate similar ligand
exchange kinetics to those of platinum (Pt II) while displaying only
low toxicity, which in part is believed to be due to the ability to
mimic iron in binding to plasma proteins including transferrin
and albumin (Allardyce and Dyson, 2001). Transport and seques-
tration of Ru into tumour cells may be mediated via protein
transport and receptor mediated uptake (Guo and Sadler, 1999).
Due to differing ligand geometry between their complexes, Ru
compounds bind to DNA forming predominately inter-strand
crosslinks as opposed to the intra-strand crosslinks favoured by
cisplatin (Fruhauf and Zeller, 1991; Gallori et al, 2000). In addi-
tion, non-nuclear targets, such as the mitochondrion and the cell
surface, have also been implicated in the antineoplastic activity of
Ru complexes, particularly in the case of the clinically investigated
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www.bjcancer.comRu(III) antimetastatic drug (trans-RuCl4(DMSO)Im)(ImH)
(NAMI-A) (Bergamo et al, 2000). Thus, Ru complexes offer the
potential over Pt (II) complexes of reduced toxicity, a novel
mechanism of action, the prospect of non-cross resistance (Zeller
et al, 1991; Coluccia et al, 1993) and a different spectrum of activ-
ity. Previous investigators have focused on Ru(III) complexes as
potential antitumour agents (Keppler et al, 1987; Berger et al,
1989; Seelig et al, 1992). In the present study, a series of novel
Ru(II) organometallic arene complexes (Morris et al, 2001) have
been evaluated for activity in both in vitro and in vivo models of
human ovarian cancer, and cross-resistance proﬁles established in
cisplatin and multi-drug resistant (MDR) variants.
MATERIALS AND METHODS
Investigational agents
The 13 novel Ru(II) organometallic arene compounds (for formu-
lae see Figure 1) were synthesised and chemically characterised as
described in detail (Morris et al, 2001) and are quoted in the
following patents: PCT/GB00/04144 and PCT/GB01/02824. All
compounds were salts with PF6
7 as counter anion. Cisplatin,
carboplatin and doxorubicin were obtained from the Western
General Hospital pharmacy.
Cell lines
The A2780 human ovarian cancer cell line and its MDR counter-
part 2780
AD were kindly provided by Drs TC Hamilton and RF
Ozols, Fox Chase Cancer Center, Philadelphia, USA. 2780
AD was
cultured in the presence of 2 mM doxorubicin, which was removed
1 week prior to experimentation with the Ru(II) compounds. The
A2780cis cell line was obtained from the ECACC (European collec-
tion of cell culture, Salisbury, UK). Cells were grown as monolayers
in RPMI 1640 medium with L-glutamine (Gibco BRL, Paisley, UK)
supplemented with 5% foetal calf serum and penicillin
(110 U ml
71) and streptomycin (100 mgm l
71) and were main-
tained under standard tissue culture conditions of 378C and 5%
CO2. Experiments were performed on cells within 10 passages of
each other.
In vitro growth inhibition assays
The human ovarian cells were added at a density of 1610
4 cells
per well to 24-well tissue culture trays (Falcon Plastics, Becton
Dickinson, Lincoln Park, NJ, USA) and allowed to grow for 72 h
before addition of the Ru(II) arene complexes. Stock solutions of
the ruthenium compounds were made up fresh in deionised water
and sonicated to ensure complete dissolution. These stock solutions
were diluted with media to give ﬁnal concentrations ranging
between 0.1 and 100 mM. All the compounds were evaluated at
each concentration in duplicate wells, and complete assays were
repeated a minimum of three times. Cisplatin or carboplatin was
employed as a positive and comparative control in each experi-
ment. After 24-h exposure the drug-containing medium was
removed, the cells washed with phosphate buffered saline (PBS)
and fresh medium was added. Cell number was assessed after a
further 72 h growth using a Coulter counter (Coulter Electronics
Ltd, Luton, UK) and the IC50 values (concentration of drug caus-
ing 50% growth inhibition) calculated by linear regression analysis
comparing the inhibitory effects of the drugs against the growth of
untreated cells.
Co-incubation of human ovarian cell lines with verapamil
or 2'deoxy-5-azacytidine (DAC)
Cells were cultured in 24-well plates as above. Verapamil (50 mM,
Sigma Chemical Co., Poole, UK) was added concomitantly with
the Ru(II) test compounds or Pt(II) compounds and doxorubicin
control for 24 h and growth inhibition was then established as
above. DAC (0.5 mM, Sigma) was added to cells for 3 days prior
to being removed with PBS washes and then the cells were treated
with cisplatin for 24 h and growth inhibition was then established
as above.
Immunoblotting for MLH1
A2780, A2780cis and 2780
AD cells were plated down at a density of
5610
5 cells per well in 6-well trays and harvested when 70%
conﬂuent. Extracts were prepared by suspending the cell pellets
in 50 mM HEPES (pH7.4), 1% Triton X-100, 150 mM NaCl,
5m M EDTA and 0.5% sodium deoxycholate in the presence of a
standard cocktail of protease inhibitors (Sigma). Protein concentra-
tions were determined by the Bio-Rad protein assay (Bio-Rad,
Richmond, CA, USA). Samples (20 mg) were denatured and sepa-
rated on a 10% SDS polyacrylamide gel before being transferred
to nitrocellulose and probed using a mouse monoclonal antibody
for hMLH1 (Clone G168-15, Pharmingen). Blots were visualised
by ECL detection (Santa Cruz). Levels of protein loading were
examined using an actin antibody (Calbiochem). In a separate
study, A2780 and A2780cis cells were treated with 10 mM DAC
for 3 days prior to protein extraction and SDS polyacrylamide
gel electrophoresis as above.
Antitumour activity in human ovarian cancer xenografts
The antitumour activity of the novel Ru(II) organometallic arene
complexes was evaluated in A2780, 2780
AD and A2780cis xeno-
grafts growing in nu/nu mice essentially as described previously
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R1
R2 R4
R3
COMPOUND R1 R2 R3 R4
RM100                p-cymene                Cl         CH3CN         CH3CN
RM101                p-cymene                Br         CH3CN         CH3CN
RM114                p-cymene                Cl            Cl           isonicotinamide
RM116                p-cymene                Cl               H2NCH2CH2NH2
RM118                    C6H6                      I                H2NCH2CH2NH2
RM119                    C6H6                    Cl              H2NCH2CH2NH2
RM121                p-cymene                  I                H2NCH2CH2NH2
RM125              C6H5CO2CH3              Cl              H2NCH2CH2NH2
RM168           C6H5CO2CH2CH3         Cl              H2NCH2CH2NH2
RM175                   C6H5C6H5                 Cl              H2NCH2CH2NH2
HC11          Tetrahydroanthracene      Cl              H2NCH2CH2NH2
HC27            Dihydroanthracene        Cl        H2N(CH2)2NH(CH2CH3)
HC29                    C6H5C6H5                Cl          H2N(CH2)2NH(CH2CH3)
Ru
Figure 1 Molecular formulae of novel Ruthenium (II) organometallic
complexes.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1652–1657(Cummings et al, 1996). The three xenografts were established
from their respective cell lines by subcutaneous implantation of
5610
6 cells in serum free media in the ﬂank of animals. The
resultant xenografts were subjected to regular pathologic examina-
tion to conﬁrm the human ovarian cancer phenotype. All animal
experiments were carried out with local and The Imperial Cancer
Research Fund ethical committee approval. The ethical guidelines
that were followed meet the standards required by the UKCCCR
guidelines (Workman et al, 1998). Female nu/nu mice were
implanted with 2–3 mm
3 fragments of viable tumour and left
for approximately 3–4 weeks. Animals were randomised into
control and drug treated groups, each of which contained 5–10
mice. Ru (II) complexes were administered as 10% DMSO solu-
tions in sterile saline and cisplatin as a solution in sterile saline
both at a volume of 0.1 ml/10 g of body weight i.p. Tumour
volumes were determined by calliper measurement and calculated
using the formula: volume=0.56length6width
2. Relative tumour
volume (RTV) was then calculated for each individual tumour
by dividing tumour volume on day t by the tumour volume on
day 16100%. T/C (%) values were calculated as the mean tumour
volume of the drug treated group/mean tumour volume of the
control group6100 from the data generated as indicated below.
Antitumour activity studies were performed on either two or three
separate occasions.
RESULTS
Structure activity relationship for Ru(II) organometallic arene
complexes in A2780 human ovarian cancer cells
The 13 organometallic complexes were initially screened against
the platinum sensitive human ovarian cancer cell line A2780 in
order to establish a baseline level of growth inhibitory activity
(Brown et al, 1993). A broad range of IC50 values was obtained
(see Table 1) with two compounds (RM175 and HC29) equipotent
to carboplatin (6 mM), one compound (HC11) equipotent to
cisplatin (0.6 mM) and one compound (HC27) intermediate in
potency between the two platinum complexes. Three compounds
(RM 100, 101 and 114) recorded values greater than 100 mM and
were deﬁned essentially as inactive, and the remaining six
compounds were of intermediate value (IC50,9–5 6mM). Of inter-
est, RM100, RM101 and RM114 when originally tested shortly after
synthesis yielded IC50 values of 7, 8 and 11 mM respectively, but
these decayed over a period of 12 weeks to 4100 mM even while
stored in the solid state at 48C. These compounds alone contained
more reactive monodentate ligands such as acetonitrile at positions
R3 and R4 (see Figure 1) in comparison to the more stable chelat-
ing ligand ethylenediamine (en) or N-ethyl ethylenediamine
employed in the remaining compounds. Substitution of the
proposed halide reactive centre (R2, Figure 1) with iodide as
opposed to chloride had little effect on in vitro potency (compare
RM118 with RM119 and RM116 with RM121). Minor chemical
alterations to the en chelating ligand (HC29 vs RM175, Figure 1
and Table 2) also had little effect on potency. However, substitu-
tion at position R1 (the arene ligand) from benzene (RM119) to
p-cymene (RM116) to biphenyl (RM175) to dihydroanthracene
(HC27) to tetrahydroanthracene (HC11) increasing overall hydro-
phobicity resulted in a large increase in growth inhibitory activity
from (IC50) 17 to 10 to 5 to 2 to 0.5 mM. The arene ligand is
believed to play a role in preventing oxidation of the ruthenium
from oxidation state II (the proposed biologically active form) to
oxidation state III (proposed inactive, prodrug form) (Allardyce
and Dyson, 2001; Morris et al, 2001). It may also facilitate cellular
uptake of the compounds.
Cross resistance proﬁles of Ru(II) organometallic arene
complexes
The fold resistance values for the six most active compounds
RM116, 121, 175 and HC11, 27 and 29 in the 2780
AD MDR and
A2780cis cisplatin resistant variants are listed in Table 2. Compared
to the parental cell line (A2780), a relatively high degree of cross-
resistance was observed in 2780
AD ranging from a factor of 15 for
RM116 up to 4100 for HC11 and this is compared to 87-fold for
doxorubicin, the original selection agent (Louie et al, 1986) (see
Table 2). In addition, there was an eight-fold level of resistance
to cisplatin in 2780
AD. By contrast, in A2780cis cells the six orga-
nometallic complexes together with doxorubicin were completely
non-cross resistant, while cisplatin and carboplatin were both 10-
fold cross resistant (Table 2).
Mechanisms of drug resistance
Verapamil has been shown to effectively abrogate P-gp mediated
active efﬂux of anticancer drugs in ovarian cancer cells by compe-
titive inhibition of drug transport and reverse multi-drug resistance
(Rogan et al, 1984). The inﬂuence of verapamil on the level of
cross-resistance in 2780
AD to RM175, cisplatin and doxorubicin
was evaluated. With doxorubicin, 50 mM verapamil restored the
chemosensitivity of the MDR cell line back to that of the parental
cell line (Figure 2). In a previous study we have demonstrated that
verapamil was able to completely abolish doxorubicin active efﬂux
in 2780
AD (Cummings et al, 1996). As anticipated, verapamil had
little effect on the activity of cisplatin, consistent with its known
lack of recognition by P-gp (Allen et al, 2000). In the case of the
Ru(II) compound RM175, verapamil was also highly effective at
restoring sensitivity (Figure 2). Here, cross resistance fell from a
factor of 38 to only three-fold.
Cisplatin resistance is frequently associated with loss of proﬁ-
ciency of the mismatch repair pathway due to methylation and
silencing of the MLH1 gene (Brown et al, 1997; Plumb et al,
2000). The A2780cis cell line was conﬁrmed to lack MLH1 protein
as well as 2780
AD, while the parental cell line expressed the protein
(Figure 3a). Treatment with the demethylating agent DAC had
little effect on MLH1 protein levels in parental A2780 cells (Figure
3b). However, it recovered expression of the protein in the
A2780cis cell lines almost back to that of the wild-type cells (Figure
3b). In addition, DAC was able to partially reverse drug resistance
to cisplatin in A2780cis cells by a factor of two-fold.
Antitumour activity of RM175
In preliminary studies it was established that the maximum toler-
ated dose (MTD) of cisplatin was 10 mg kg
71 i.p. as a single
administration, in keeping with previous reports (Langdon et al,
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Table 1 IC50 values of Ru(II) complexes in A2780 cells after a 24 h drug
exposure
Ru(II) complex IC50 (mM)*
RM100 4100
RM101 4100
RM114 4100
RM116 10+1.1
RM118 20+8.9
RM119 17+8.3
RM121 9+1.6
RM125 56+0.7
RM168 52+2.3
RM175 5+0.4
HC11 0.5+0.1
HC27 2+0.4
HC29 6+0.7
Cisplatin 0.6+0.06
Carboplatin 6.0+0.7
*Results expressed as mean+s.e. of 5three separate experiments.
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71 RM175 on
days 1 and 5 without signiﬁcant weight loss. At the above dose
regimen, RM175 produced a signiﬁcant growth delay against the
A2780 xenograft representing a T/C value of 46% on day 16
(Student’s t-test compared to controls, Figure 4a). By comparison
cisplatin at its MTD produced a T/C value of 23% on day 16 of the
study (Figure 4a). In the A2780cis xenograft RM175 growth inhi-
bitory activity was maintained (T/C 51%, day 13) and was
signiﬁcantly greater than that of cisplatin on day 8 (P=0.03) and
day 13 (P=0.01) (Figure 4b). Cisplatin was active in the 2780
AD
xenograft, although not to the same level as the parental xenograft
(T/C value 55 %, day 14), while RM175 was inactive against
2780
AD (Figure 4c). Thus, the patterns of activity established in
vitro for both RM175 and cisplatin were mirrored to a large degree
in vivo, making the A2780 cell line and its two resistant clones an
attractive pre-clinical screen for evaluating new agents in this class
(Workman et al, 1998).
DISCUSSION
The aim of the present study has been to evaluate the in vitro and
in vivo the activity of a novel series of Ru(II) organometallic arene
complexes and identify potential resistance mechanisms, with the
intention of feeding back this information into rational design of
second generation compounds. Ru(II) arene complexes with in
vitro potency greater than that of carboplatin and equal to cisplatin
were identiﬁed, and in vivo xenograft activity was established in
human ovarian cancer. A pattern of cross-resistance emerged for
the Ru(II) arene compounds, quite distinct from that of cisplatin
and carboplatin, characterised by non-cross resistance in cisplatin
resistant cells (and xenograft) but cross-resistance in multi-drug
resistant (MDR) cells (and xenograft).
The 2780
AD cell line utilised in the present study displays the
classic MDR phenotype mediated via over-expression of the
170 kD plasma membrane glycoprotein P-gp and reduced cellular
drug accumulation (Cummings et al, 1995, 1996). In addition,
multi-drug (associated) protein 2 (MRP2) is up-regulated in this
cell line (Cummings et al, unpublished observations). Over-expres-
sion of MRP2 is a common phenomenon in human ovarian cell
lines (including A2780) that display higher levels of resistance to
cisplatin (Borst et al, 2000; Kool et al, 1997). However, MLH1
protein was also shown to be absent, which may be responsible
for the eight-fold level of drug resistance observed with cisplatin
in 2780
AD (Table 2). P-pg displays striking substrate speciﬁcity
for naturally occurring hydrophobic molecules, particularly those
carrying a positive charge but does not transport cisplatin (Endicott
and Ling, 1989; Gottesman and Pastan, 1993; Seelig et al, 2000). By
contrast, MRPs 1, 2 are 3 are well recognised as transporting organ-
ic anions, or neutral compounds as either glutathione (GSH)
conjugates or co-transported with GSH (Borst et al, 2000; Ishikawa
et al, 2000; Zeng et al, 2000). The six organometallic complexes
investigated for cross-resistance in the present study (see Table 2
and Figure 1) exhibit both of the features – hydrophobicity and
a cationic centre – that facilitate substrate recognition by P-pg
(Endicott and Ling, 1989; Gottesman and Pastan, 1993; Seelig et
al, 2000). Thus, it is likely that the cross-resistance to Ru(II) arene
complexes observed in the 2780
AD cell line is due, at least in part,
to recognition and active efﬂux by P-pg. The almost complete
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Table 2 Cross resistance proﬁles of Ru(II) complexes in cisplatin
resistant A2780cis cells and multi-drug resistant 2780
AD cells compared
to parental A2780 cells
Fold resistance
Complex A2780cis 2780
AD
RM116 0.6 15
RM121 0.4 27
RM175 1.0 38
HC11 1.0 4100
HC27 1.0 4100
HC29 0.7 40
Cisplatin 10 8.0
Carboplatin 10 ND
Doxorubicin 1.0 87
ND=not determined.
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Verapamil
100
90
80
70
60
50
40
30
20
10
0
F
o
l
d
 
r
e
s
i
s
t
a
n
c
e
8 6
38
3
87
0.2
CDDP RM175 Doxorubicin
Figure 2 Effect of co-administration of 50 mM-verapamil on the degree
of cross-resistance exhibited in the 2780
AD multi-drug resistant cell line
to doxorubicin, cisplatin and the novel Ru(II) arene complex RM175 (for
structure see Figure 1).
A2780 A2780cis 2780
AD
1        2      3      4      5     6      7     8       9
MLH1
Actin
MLH1
Actin
MLH1
Actin
Cell line          A2780        A2780     A2780cis   A2780cis
DAC               –        –        +       +      –       –       +      +
1          2        3       4      5      6       7     8      
A
B
Figure 3 (A) MLH1 protein levels in the A2780 (lanes 1–3), 2780cis
(lanes 4–6) and 2780
AD (lanes 7–9) determined by Western blot analysis.
(B) MLH1 protein levels in the A2780 and A2780cis cell lines plus (+) or
minus (7) co-incubation with 10 mM 2'deoxy-5-azacytidine (DAC) for 3
days prior to protein extraction and SDS polyacrylamide gel electrophor-
esis and Western blotting.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1652–1657reversal of RM175 drug resistance by verapamil suggests that P-gp
may function as the pre-dominant or even sole drug-resistance
mechanism in this cell line. It is noteworthy that the more hydro-
phobic the organometallic complex, the higher the level of intrinsic
drug potency in A2780 parental cells, but also the greater the
degree of cross-resistance in 2780
AD.
The mechanism of resistance to cisplatin in A2780cis cells
remains poorly characterised (ECACC catalogue, European collec-
tion of cell culture, Salisbury, UK). A number of potential
resistance mechanisms to cisplatin and analogous alkylating agents
in a variety of A2780 clones have been reported previously includ-
ing:
(a) loss of proﬁciency of the mismatch repair pathway (MMR) due
to methylation and silencing of the hMLH1 gene (Brown et al,
1997) (Plumb et al, 2000);
(b) accumulation of the mutant (inactive) form of the p53 tumour
suppressor gene (Brown et al, 1993);
(c) elevated GSH cellular content and a concomitant increase in
expression of MRP2 (Kool et al, 1997) and
(d) altered DNA damage recognition, cellular signalling and DNA
repair (Roy et al, 2000).
Since the novel Ru(II) organometallic complexes were unaffected
by these putative mechanisms, it was important to establish the
mechanism(s) of cisplatin resistance in A2780cis. In the present
study, Western blot analysis of the MLH1 protein in A2780 paren-
tal (cisplatin sensitive) cells and A2780cis (cisplatin resistant) cells
clearly demonstrated that it was not present in the resistant cell
line. Treatment of A2780cis cells with DAC re-established MLH1
protein expression and partially reversed drug resistance to cispla-
tin. DAC has recently been shown to reverse cisplatin drug
resistance in the related A2780/cp70 xenograft by demethylation
of the hMLH1 gene promoter (Plumb et al, 2000). Thus, it would
appear that a deﬁciency in MMR is at least partially responsible for
the expression of cisplatin resistance in the A2780cis cell line and
by implication that MMR proﬁciency is not a prerequisite in the
mechanism of action of the novel Ru(II) compounds, consistent
with a number of other ruthenium complexes (Fruhauf and Zeller,
1991; Zeller et al, 1991; Coluccia et al, 1993; Kelland, 1999). MMR
deﬁciency usually accounts for a 2–3-fold level of resistance (Fink
et al, 1998) and in the present study co-administration of DAC was
only able to reverse cisplatin resistance in A2780cis by two-fold
indicating the possibility of the presence of other resistance
mechanisms in this cell line. At present, studies are in progress
in the A2780cis cell line to investigate the role of drug transport,
expression of drug transporters, levels of GSH and the role of p53.
In summary, a series of novel Ru(II) organometallic arene
complexes have been evaluated for activity both in vitro and in vivo
in human ovarian cancer. Preliminary structure activity data have
been obtained suggesting that stable (chelating) bystander ligands,
a more hydrophobic arene ligand (possibly to enhance cellular
penetration) and a single ligand exchange centre are associated
with reproducible and increased growth inhibitory activity. These
properties, particularly the hydrophobic arene group may also
promote recognition by P-gp. Reduced in vivo toxicity and non
cross-resistance in cisplatin resistant models in vitro and in vivo
have been conﬁrmed, justifying further development of this novel
and interesting group of metal complexes.
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Figure 4 Antitumour activity of RM175 administered on days 1 and 5 at
25 mg kg
71 i.p. vs cisplatin administered on day 1 at 10 mg kg
71 i.p. (A)
Effect of RM175 and cisplatin on the A2780 human ovarian cancer xeno-
graft. (B) Effect of RM175 and cisplatin on the A2780cis human ovarian
cancer xenograft and (C) effect of RM175 and cisplatin on the 2780
AD hu-
man ovarian cancer xenograft. Statistical signiﬁcance was evaluated by Stu-
dent’s t-test comparing the drug treated groups at speciﬁc time points
against the control group: *P50.05. In the case of A2780, cisplatin was
more active than RM175 on days 14 and 16 (P50.01), while in
A2780cis RM175 was more active than cisplatin on days 8 and 13
(P50.05).
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